The Biosecure Act was first proposed by the US government late last year due to concerns about national security and how genetic and other biological data could be misused by foreign adversarial governments with a focus on China. The current status of the Biosecure Act is that it was passed by the US House of Representatives on Sep 9, with a vote of 306-81 for the bill across both parties. "There's actually two versions in the Senate, one that is the House version, and then one that's a little bit different," explained Matthew Wetzel, a Goodwin partner that specializes in Life Sciences Regulatory & Compliance, in an interview. "The Senate could pass the version that's identical to the House version, in which case it would just go to President Biden for signature. If they use their original version that's a little bit different. Then they have to go back to the house. They've got to figure out a common version. Both houses have to approve it," he said to Outsourcing Pharma.